Science Explorer Interactive view Map
Company · Palo Alto · United States

KalVista Pharmaceuticals (United States)

ir.kalvista.comROR OpenAlex
Research works
90
▲ 554% vs 2013–17
Citations
8.2k
92.0 per fractional work
Top-10% rate
24.9%
record average 16.5%
Open access
51%
world 28%

Not ranked overall: KalVista Pharmaceuticals (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 1.57× its world share, 2 worksBiochemistry, Geneti…Immunology and Microbiology: 10.85× its world share, 2 worksImmunology and Micro…Neuroscience: 0.26× its world share, 0 worksNeuroscienceComputer Science: 0.24× its world share, 0 worksComputer ScienceEngineering: 0.12× its world share, 0 worksEngineeringEnvironmental Science: 0.20× its world share, 0 worksEnvironmental ScienceMaterials Science: 0.12× its world share, 0 worksMaterials ScienceHealth Professions: 0.79× its world share, 0 worksHealth ProfessionsMedicine: 3.35× its world share, 13 worksMedicineNursing: 1.69× its world share, 0 worksNursingEconomics, Econometrics and Finance: 2.33× its world share, 1 worksEconomics, Econometr…Psychology: 0.41× its world share, 0 worksPsychologySocial Sciences: 0.13× its world share, 0 worksSocial Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 10.8×. Every wedge is a field page.

Who are the top researchers at KalVista Pharmaceuticals (United States)?

Ranked on the composite score, Paul Ponath, Paul Audhya and Christopher Yea lead among researchers whose main affiliation is KalVista Pharmaceuticals (United States).

  1. 1 Paul Ponath United States · #1,229,234 worldwide 32 citations · 16 works
  2. 2 Paul Audhya United States · #1,289,719 worldwide 11 citations · 21 works
  3. 3 Christopher Yea United States · #1,426,783 worldwide 22 citations · 15 works
  4. 4 Sherry Danese United States · #1,591,255 worldwide 7 citations · 15 works
All ranked researchers at KalVista Pharmaceuticals (United States)

Which keywords describe research at KalVista Pharmaceuticals (United States)?

By fractional works in 2022–2025, weighted toward what it does more of than the world: Hereditary Angioedema, Kinin Receptor Family, Inhibitors, Efficacy, Gene Therapy, Factor VIII, Hemophilia and Inflammation.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 13 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 13 words, with their numbers
  1. Hereditary Angioedema7▲ 1999×1 topic
  2. Kinin Receptor Family7▲ 1999×1 topic
  3. Inhibitors2▲ 239×2 topics
  4. Efficacy2▲ 121×2 topics
  5. Gene Therapy2▲ 46×2 topics
  6. Inflammation2▲ 4.2×5 topics
  7. Factor VIII2▲ 584×1 topic
  8. Hemophilia2▲ 584×1 topic
  9. Allergic Disease1▲ 403×1 topic
  10. Mast Cells1▲ 403×1 topic
  11. Genetics1▲ 8.1×3 topics
  12. Signaling1▲ 101×1 topic
  13. mTOR1▲ 390×1 topic

Which research topics does KalVista Pharmaceuticals (United States) publish most on?

By volume in 2022–2025: Coagulation, Bradykinin, Polyphosphates, and Angioedema, Hemophilia Treatment and Research, Mast cells and histamine and PI3K/AKT/mTOR signaling in cancer.

Coagulation, Bradykinin,…7Coagulation, Bradykinin, Polyphosphates, and Angioedema: 7 fractional worksHemophilia Treatment and Research: 2 fractional worksMast cells and histamine: 1 fractional worksPI3K/AKT/mTOR signaling …1PI3K/AKT/mTOR signaling in cancer: 1 fractional worksComplement system in diseases: 1 fractional worksHealth Systems, Economic Evaluations, Quality of Life: 0 fractional worksAntiplatelet Therapy and Cardiovascular Diseases: 0 fractional worksPharmaceutical Economics and Policy: 0 fractional worksAutoimmune Bullous Skin Diseases: 0 fractional worksAsthma and respiratory diseases: 0 fractional works
GeneticsHematologyImmunologyMolecular Biology4 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Coagulation, Bradykinin, Polyphosphates, and Angioedema Genetics 7 works
  2. 2 Hemophilia Treatment and Research Hematology 2 works
  3. 3 Mast cells and histamine Immunology 1 works
  4. 4 PI3K/AKT/mTOR signaling in cancer Molecular Biology 1 works
  5. 5 Complement system in diseases Immunology 1 works
  6. 6 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 0 works
  7. 7 Antiplatelet Therapy and Cardiovascular Diseases Cardiology and Cardiovascular Medicine 0 works
  8. 8 Pharmaceutical Economics and Policy Economics and Econometrics 0 works
  9. 9 Autoimmune Bullous Skin Diseases Pathology and Forensic Medicine 0 works
  10. 10 Asthma and respiratory diseases Physiology 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available51.4%not open48.6%

World: 28% of research is openly available.

with international co-authors34.5%domestic only65.5%

World: 19% is written across borders.

How has KalVista Pharmaceuticals (United States)'s research output changed?

Output in 2018–2022 was 554% higher than in 2013–2017.

1990200020102020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Palo Alto

All research institutions in Palo Alto

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.